Navigation Links
MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
Date:6/14/2010

WOONSOCKET, R.I., June 14 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).

In an earlier Phase IIa study, MCT-125 was tested on 138 patients suffering from PMSF.  MCT-125 was shown to be effective within 4 weeks of administration, was active across all multiple sclerosis (MS) disease severity assessment scales, and on patients regardless of MS disease sub-type (primary progressive, secondary progressive and relapsing-remitting).

MCT-125 is a fixed dose, orally delivered, combination therapeutic acting on noradrenergic neurons and tyrosine hydroxylase to block the reuptake of noradrenaline with little or no direct action on serotoninergic neurons.  The synthesis of noradrenaline in noradrenergic neurons is tightly regulated by tyrosine hydroxylase acting as the key rate-limiting step.  MCT-125 is thought to lead to the greater availability of noradrenaline in the central nervous system resulting in a decrease in fatigue levels.

Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the myelin sheath insulating neurons in the brain and spinal cord.  Approximately 350,000 individuals have been diagnosed with MS in the United States, and m
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
2. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
3. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
4. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
5. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
6. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
7. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
8. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
9. Accuray Hires General Manager for Japan
10. Ascension Orthopedics Hires Key Senior Executives
11. Accuray Hires General Manager for the EIMEA Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Casen Buswell has a ... muscles to harden.  His case is one of only 14 ... world.  The only hospital in the United States ... world, offering treatment with the dual wave-length laser, is Methodist ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... Sept. 18, 2014  Decision Resources Group finds ... the United States , 54 percent of ... inhibitor Tafinlar for BRAF -mutation-positive unresectable or ... prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current non-prescribers ... percent and 43 percent, respectively) expects to prescribe ...
(Date:9/18/2014)... PLYMOUTH MEETING, Pa. , Sept. 18, 2014 /PRNewswire/ ... of innovative approaches to diagnosing and treating Autism Spectrum ... an Exclusive License Agreement with The Research Foundation for ... this Agreement, Iliad will provide a new biomarker to ... associated with susceptibility to ASD. This biomarker is expected ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3
... , COLLEGE STATION, ... , MD, FACS, of The Texas Institute for Thyroid and Parathyroid ... College Station Medical Center in College Station, Texas . ... in North America to be recognized by Intuitive Surgical ...
... , Jan. 14 In the keynote address at ... Lechleiter , Ph.D., chairman and CEO of Eli Lilly and Company, ... edge in innovation and improving our focus on medical innovation,s richest ... in the coming decade.  His speech focused on bioscience innovation, a ...
Cached Medicine Technology:Milestone Achieved in Revolutionary Robotic Thyroid Surgery 2Lilly CEO Stresses Human Element in Driving Medical Innovation 2Lilly CEO Stresses Human Element in Driving Medical Innovation 3
(Date:9/18/2014)... A unique partnership to support private efforts to provide ... provide a model for similar efforts should federal officials ... of reform of the VA health system, according to ... Veterans Initiative, a joint project of philanthropic groups and ... patient care, education and other services to veterans and ...
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 ItsHot.com, ... NY, is now offering a 65-80% discount on its ... a whopping 71% off on its 14K Gold Pave ... diamond band can now be bought for just $775. ... 406147. , Talking about this diamond band, a representative ...
(Date:9/18/2014)... Pathways Home Health & Hospice has ... Medical Director. Prior to accepting the directorship, Brown ... Pathways KIDS, adult palliative care, and hospice teams that ... Counties. , In her new position, Brown is ... program. She will supervise five medical directors who are ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
(Date:9/18/2014)... (Sept. 17, 2014) -- Two independent groups of ... the University of Kentucky, and Charles Lowenstein, MD, ... studies exploring the role that a gene called ... , According to Whiteheart, previous genome-wide association studies ... factor that regulates a protein called Von Willebrand ...
Breaking Medicine News(10 mins):Health News:Study provides insight about providing private mental health service to veterans 2Health News:Study provides insight about providing private mental health service to veterans 3Health News:ItsHot.com Now Offering 65-80% Discount on its Striking Collection of Diamond Wedding Bands 2Health News:Dr. Ellen Brown Promoted to Chief Medical Director at Pathways Home Health & Hospice 2Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2
... gap is alive and well in heart disease, a new international ... to treatment in both heart attack and severe chest pain. ... twice as likely as men to have normal or mild results ... blockage taking up more than 50 percent of any one blood ...
... ... Flows Increase, BIRMINGHAM, Ala., May 6 HealthSouth,Corporation (NYSE: ... first quarter ended March 31, 2008. Compared to the,first quarter of ... net income increased by $76.4 million., "The results of the ...
... and,Mississippi still working to recover from the Hurricane Katrina ... Department of,Health and Human Services (HHS)., "HHS continues ... health care,problems created by Hurricane Katrina," Secretary Mike Leavitt ... make sure the citizens of these,states have continued access ...
... Today at 5:30 p.m. EDT, FRAZER, Pa., ... that a Joint Advisory Committee to the U.S. ... approval of an expanded,label for FENTORA(R) (fentanyl buccal ... opioid-tolerant patients with chronic pain conditions.,The panel expressed ...
... have shown for the first time that thrombopoietin (TPO), ... to increase platelet count in cancer patients during chemotherapy, ... heart attack. , The study, led by ... the division of cardiothoracic surgery, was published in the ...
... now register to attend TCT2008 (Transcatheter Cardiovascular Therapeutics), ... Foundation. TCT gathers leading medical researchers and clinicians ... developments in the field of interventional cardiology and ... state-of-the-art techniques and training to interventional cardiologists around ...
Cached Medicine News:Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 2Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 2Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 4Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 5Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 6Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 7Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 8Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 9Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 10Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 11Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 12Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 13Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 14Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 15Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 16Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 17Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 18Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 19Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 20Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 21Health News:Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 3Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 4Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 5Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 6Health News:Naturally-occuring protein may be effective in limiting heart attack injury and restoring function 2Health News:Media registration now open for TCT2008 2
Inquire...
... Novas Point-of-Care Manager is ... gas and critical care ... the industry. PDM ... workstation designed to effortlessly ...
... The ISI Micro Nest is the wall-mounted organizer ... a variety of sizes and diameters. The Micro ... the right brush for the cleaning task. These ... specifically for those hard-to-clean instruments such as cannulas. ...
... is the non-silicone lubricant designed to "spot" ... lubricates sticky pivot points, hinges, box joints ... allows you to lubricate with precision. Safe ... Ideal for carts, hinges, medical equipment, and ...
Medicine Products: